Why Definium Therapeutics Stock Gained 340% This Year Without Any Product Revenue

New York, Sunday, 23 August 2026.
Definium Therapeutics has delivered a stunning 340% gain over the past year. Investors are betting heavily on its late-stage psychiatric clinical trials, despite zero current product revenue.